SAN DIEGO — Since Herceptin’s approval in 1998, breast cancer has been reshaped from a near-term death sentence into — in many cases — a chronic disease. Now, researchers hope daraxonrasib from Revolution Medicines will launch the same …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844